This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (120)  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in JAMA  Topic Collections  • Pulmonary Diseases  • Chronic Obstructive Pulmonary Disease  • Quality of Care  • Evidence-Based Medicine  • Alert me on articles by topic  Social Bookmarking   What's this?

Scientific Review

Don D. Sin, MD, MPH; Finlay A. McAlister, MD, MSc; S. F. Paul Man, MD; Nick R. Anthonisen, MD, PhD

JAMA. 2003;290:2301-2312.

Context  The care of patients with chronic obstructive pulmonary disease (COPD) has changed radically over the past 2 decades, and novel therapies can not only improve the health status of patients with COPD but also modify its natural course.

Objective  To systematically review the impact of long-acting bronchodilators, inhaled corticosteroids, nocturnal noninvasive mechanical ventilation, pulmonary rehabilitation, domiciliary oxygen therapy, and disease management programs on clinical outcomes in patients with COPD.

Data Sources  MEDLINE and Cochrane databases were searched to identify all randomized controlled trials and systematic reviews from 1980 to May 2002 evaluating interventions in patients with COPD. We also hand searched bibliographies of relevant articles and contacted experts in the field.

Study Selection and Data Extraction  We included randomized controlled trials that had follow-up of at least 3 months and contained data on at least 1 of these clinical outcomes: health-related quality of life, exacerbations associated with COPD, or death. For pulmonary rehabilitation, we included studies that had a follow-up of at least 6 weeks. Using standard meta-analytic techniques, the effects of interventions were compared with placebo or with usual care. In secondary analyses, the effects of interventions were compared against each other, where possible.

Data Synthesis  Long-acting ₂-agonists and anticholinergics (tiotropium) reduced exacerbation rates by approximately 20% to 25% (relative risk [RR] for long-acting ₂-agonists, 0.79; 95% CI, 0.69-0.90; RR for tiotropium, 0.74; 95% CI, 0.62-0.89) in patients with moderate to severe COPD. Inhaled corticosteroids also reduced exacerbation rates by a similar amount (RR, 0.76; 95% CI, 0.72-0.80). The beneficial effects were most pronounced in trials enrolling patients with FEV₁ between 1 L and 2 L. Combining a long-acting ₂-agonist with an inhaled corticosteroid resulted in an approximate 30% (RR, 0.70; 95% CI, 0.62-0.78) reduction in exacerbations. Pulmonary rehabilitation improved the health status of patients with moderate to severe disease, but no material effect was observed on long-term survival or hospitalization rates. Domiciliary oxygen therapy improved survival by approximately 40% in patients with PaO₂ lower than 60 mm Hg, but not in those without hypoxia at rest. The data on disease management programs were heterogeneous, but overall no effect was observed on survival or risk of hospitalization. Noninvasive mechanical ventilation was not associated with improved outcomes.

Conclusions  A significant body of evidence supports the use of long-acting bronchodilators and inhaled corticosteroids in reducing exacerbations in patients with moderate to severe COPD. Domiciliary oxygen therapy is the only intervention that has been demonstrated to prolong survival, but only in patients with resting hypoxia.

Author Affiliations: Divisions of Pulmonary Medicine (Drs Sin and Man) and General Medicine (Dr McAlister), University of Alberta, Edmonton; Institute of Health Economics, Edmonton, Alberta (Drs Sin and McAlister); and Department of Medicine, University of Manitoba, Winnipeg (Dr Anthonisen).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED LETTERS

Management of Chronic Obstructive Pulmonary Disease
Robert M. Ewart
JAMA. 2004;291(9):1066.
EXTRACT | FULL TEXT  

Management of Chronic Obstructive Pulmonary Disease
R. Graham Barr
JAMA. 2004;291(9):1066-1067.
EXTRACT | FULL TEXT  

Management of Chronic Obstructive Pulmonary Disease—Reply
Don D. Sin, S. F. Paul Man, Finlay A. McAlister, and Nick R. Anthonisen
JAMA. 2004;291(9):1067.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Contemporary Management of Chronic Obstructive Pulmonary Disease: Clinical Applications
S. F. Paul Man, Finlay A. McAlister, Nick R. Anthonisen, and Don D. Sin
JAMA. 2003;290(17):2313-2316.
ABSTRACT | FULL TEXT  

Chronic Obstructive Pulmonary Disease
Sharon Parmet, Cassio Lynm, and Richard M. Glass
JAMA. 2003;290(17):2362.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Systemic Inflammation and Inhaled Corticosteroids in COPD
Sin and Paul Man
Am. J. Respir. Crit. Care Med. 2009;179:170-171.
FULL TEXT  

Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD?
Man et al.
Eur Respir J 2008;32:1451-1457.
ABSTRACT | FULL TEXT  

Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation
Gross
Mayo Clin Proc. 2008;83:1241-1250.
ABSTRACT | FULL TEXT  

Risk for Death Associated with Medications for Recently Diagnosed Chronic Obstructive Pulmonary Disease
Lee et al.
ANN INTERN MED 2008;149:380-390.
ABSTRACT | FULL TEXT  

Patient adherence in COPD
Bourbeau and Bartlett
Thorax 2008;63:831-838.
ABSTRACT | FULL TEXT  

Airway Dimensions at Inspiratory and Expiratory Multisection CT in Chronic Obstructive Pulmonary Disease: Correlation with Airflow Limitation
Matsuoka et al.
Radiology 2008;248:1042-1049.
ABSTRACT | FULL TEXT  

A National Study of Chronic Disease Prevalence and Access to Care in Uninsured U.S. Adults
Wilper et al.
ANN INTERN MED 2008;149:170-176.
ABSTRACT | FULL TEXT  

Biomarkers in COPD: Are We There Yet?
Sin and Man
Chest 2008;133:1296-1298.
FULL TEXT  

Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: A one year evaluation of safety and tolerance
Donohue et al.
Ther Adv Respir Dis 2008;2:37-48.
ABSTRACT  

Review: Surfactant protein D: A lung specific biomarker in COPD?
Sin et al.
Ther Adv Respir Dis 2008;2:65-74.
ABSTRACT  

Screening for Chronic Obstructive Pulmonary Disease Using Spirometry: Summary of the Evidence for the U.S. Preventive Services Task Force
Lin et al.
ANN INTERN MED 2008;148:535-543.
ABSTRACT | FULL TEXT  

Quantitative Assessment of Air Trapping in Chronic Obstructive Pulmonary Disease Using Inspiratory and Expiratory Volumetric MDCT
Matsuoka et al.
Am. J. Roentgenol. 2008;190:762-769.
ABSTRACT | FULL TEXT  

Exacerbation-Free COPD: A Goal Too Far?
Rennard and Higenbottam
Proc Am Thorac Soc 2007;4:583-585.
ABSTRACT | FULL TEXT  

Oral vs IV Corticosteroids for In-hospital Treatment of COPD Exacerbations
Tashkin
Chest 2007;132:1728-1729.
FULL TEXT  

Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline from the American College of Physicians
Qaseem et al.
ANN INTERN MED 2007;147:633-638.
ABSTRACT | FULL TEXT  

Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline
Wilt et al.
ANN INTERN MED 2007;147:639-653.
ABSTRACT | FULL TEXT  

Comorbidities in older patients with HIV: A retrospective study
Magalhaes et al.
Journal of the American Dental Association 2007;138:1468-1475.
ABSTRACT | FULL TEXT  

Review: Systemic consequences of COPD
Tkac et al.
Ther Adv Respir Dis 2007;1:47-59.
ABSTRACT  

Pharmacologic Interventions in Chronic Obstructive Pulmonary Disease: Bronchodilators
Hanania and Donohue
Proc Am Thorac Soc 2007;4:526-534.
ABSTRACT | FULL TEXT  

Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
Suissa et al.
Proc Am Thorac Soc 2007;4:535-542.
ABSTRACT | FULL TEXT  

Applying Quality-of-Life Data Formally and Systematically Into Clinical Practice
Frost et al.
Mayo Clin Proc. 2007;82:1214-1228.
ABSTRACT | FULL TEXT  

Should we avoid {beta}-agonists for moderate and severe chronic obstructive pulmonary disease?: YES
Salpeter
cfp 2007;53:1290-1293.
FULL TEXT  

Faut-il eviter les -agonistes dans les cas de bronchopneumopathies chroniques obstructives moderees et graves?: OUI
Salpeter
cfp 2007;53:1294-1297.
FULL TEXT  

Systematic Review of the Chronic Care Model in Chronic Obstructive Pulmonary Disease Prevention and Management
Adams et al.
Arch Intern Med 2007;167:551-561.
ABSTRACT | FULL TEXT  

A Pooled Analysis of FEV1 Decline in COPD Patients Randomized to Inhaled Corticosteroids or Placebo
Soriano et al.
Chest 2007;131:682-689.
ABSTRACT | FULL TEXT  

Increased COPD Among HIV-Positive Compared to HIV-Negative Veterans.
Crothers et al.
Chest 2006;130:1326-1333.
ABSTRACT | FULL TEXT  

Association of Left-Heart Dysfunction with Severe Exacerbation of Chronic Obstructive Pulmonary Disease: Diagnostic Performance of Cardiac Biomarkers
Abroug et al.
Am. J. Respir. Crit. Care Med. 2006;174:990-996.
ABSTRACT | FULL TEXT  

Inhaled corticosteroids and mortality in COPD.
Sin
Thorax 2006;61:918-918.
FULL TEXT  

Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis
Barr et al.
Thorax 2006;61:854-862.
ABSTRACT | FULL TEXT  

Cooling the Fire Within: Inhaled Corticosteroids and Cardiovascular Mortality in COPD.
Sin and Man
Chest 2006;130:629-631.
FULL TEXT  

Pharmacotherapy for Mortality Reduction in Chronic Obstructive Pulmonary Disease
Sin and Man
Proc Am Thorac Soc 2006;3:624-629.
ABSTRACT | FULL TEXT  

An Official ATS Statement: Grading the Quality of Evidence and Strength of Recommendations in ATS Guidelines and Recommendations
Schunemann et al.
Am. J. Respir. Crit. Care Med. 2006;174:605-614.
FULL TEXT  

Efficacy and Safety of Inhaled Corticosteroids in Patients With COPD: A Systematic Review and Meta-Analysis of Health Outcomes
Gartlehner et al.
Ann Fam Med 2006;4:253-262.
ABSTRACT | FULL TEXT  

Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium
Good and Longo
ANN INTERN MED 2006;144:147-147.
FULL TEXT  

Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium
Niewoehner et al.
ANN INTERN MED 2006;144:148-149.
FULL TEXT  

Skeletal muscle weakness, reduced exercise tolerance, and COPD: is systemic inflammation the missing link?
Sin and Man
Thorax 2006;61:1-3.
FULL TEXT  

Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease
van der Palen et al.
Thorax 2006;61:29-33.
ABSTRACT | FULL TEXT  

Improving inhaler use in COPD and the role of patient preference
Bateman
ERR 2005;14:85-88.
ABSTRACT | FULL TEXT  

Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease
Sin et al.
Thorax 2005;60:992-997.
ABSTRACT | FULL TEXT  

Combination Therapy for Chronic Obstructive Pulmonary Disease: Clinical Aspects
Donohue
Proc Am Thorac Soc 2005;2:272-281.
ABSTRACT | FULL TEXT  

The Role of Vagal Afferent Nerves in Chronic Obstructive Pulmonary Disease
Undem and Kollarik
Proc Am Thorac Soc 2005;2:355-360.
ABSTRACT | FULL TEXT  

A Randomized Trial of Two Types of Nurse-Assisted Home Care for Patients With COPD
Coultas et al.
Chest 2005;128:2017-2024.
ABSTRACT | FULL TEXT  

Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium, a Once-Daily Inhaled Anticholinergic Bronchodilator: A Randomized Trial
Niewoehner et al.
ANN INTERN MED 2005;143:317-326.
ABSTRACT | FULL TEXT  

Inhaled Corticosteroids and Chronic Obstructive Pulmonary Disease: New and Improved Evidence?
Samet
Am. J. Respir. Crit. Care Med. 2005;172:407-408.
FULL TEXT  

Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease
Troosters et al.
Am. J. Respir. Crit. Care Med. 2005;172:19-38.
FULL TEXT  

COPD: current therapeutic interventions and future approaches
Barnes and Stockley
Eur Respir J 2005;25:1084-1106.
ABSTRACT | FULL TEXT  

Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004
Decramer et al.
Thorax 2005;60:343-349.
ABSTRACT | FULL TEXT  

Integrated care programmes for chronically ill patients: a review of systematic reviews
Ouwens et al.
Int J Qual Health Care 2005;17:141-146.
ABSTRACT | FULL TEXT  

Distribution of Receptor Targets in the Lung
Barnes
Proc Am Thorac Soc 2004;1:345-351.
ABSTRACT | FULL TEXT  

Effects of Corticosteroids on Lung Function in Asthma and Chronic Obstructive Pulmonary Disease
Donohue and Ohar
Proc Am Thorac Soc 2004;1:152-160.
ABSTRACT | FULL TEXT  

Effects of Fluticasone on Systemic Markers of Inflammation in Chronic Obstructive Pulmonary Disease
Sin et al.
Am. J. Respir. Crit. Care Med. 2004;170:760-765.
ABSTRACT | FULL TEXT  

Update in General Internal Medicine
Kroenke and Logio
ANN INTERN MED 2004;141:213-220.
FULL TEXT  

Innovations in Lung Volume Reduction: The Non-Cutting Edge
Ost et al.
Chest 2004;126:6-9.
FULL TEXT  

Review: long acting {beta}2 agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease
Small
Evid. Based Nurs. 2004;7:87-87.
FULL TEXT  

Review: long acting {beta}2-agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease
Rees
Evid. Based Med. 2004;9:79-79.
FULL TEXT  

Vagal Pas de Deux: Heart-Lung Interplay in Postexercise Heart Rate Recovery
Raymond
Chest 2004;125:1186-1190.
FULL TEXT  

Management of Chronic Obstructive Pulmonary Disease
Ewart
JAMA 2004;291:1066-1066.
FULL TEXT  

Management of Chronic Obstructive Pulmonary Disease
Barr
JAMA 2004;291:1066-1067.
FULL TEXT  

One Hundred Years of Chronic Obstructive Pulmonary Disease
Fishman
Am. J. Respir. Crit. Care Med. 2005;171:941-948.
FULL TEXT